Anti-Mouse/Rat CD90.1 (Thy-1.1) [Clone OX-7] — Purified in vivo GOLD™ Functional Grade

Anti-Mouse/Rat CD90.1 (Thy-1.1) [Clone OX-7] — Purified in vivo GOLD™ Functional Grade

Product No.: C851

[product_table name="All Top" skus="C392"]

- -
- -
Clone
OX-7
Target
CD90.1
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
CD90, CD90.1, Thy-1, Thy1.1, Thy1.2, Thy-1.2
Isotype
Mouse IgG1
Applications
FC
,
IF
,
IHC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Rat
Host Species
Mouse
Recommended Dilution Buffer
Immunogen
Rat thymocyte Thy-1 antigen
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<1.0 EU/µg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.0-7.5, 0.005% pS80 stabilizing buffer, with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Additional Applications Reported In Literature ?
FC
IF
FA
IHC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone OX-7 activity is directed against both rat and murine CD90/Thy-1.
Background
CD90/Thy-1 (murine CD90.1/Thy-1.1) is a cell surface glycoprotein that was the first protein of the immunoglobulin superfamily to be discovered5. The 25 kDa core protein is N-glycosylated at three sites, leading to isoforms with a range of molecular masses (25-37 kDa). CD90 is composed of a single V-like immunoglobulin domain anchored by a disulfide bond between Cys 28 and Cys 104. Despite its lack of an intracellular domain, CD90 is located in the outer leaflet of lipid rafts at the cell membrane, allowing signaling functions by cis- and trans-interactions with a variety of proteins, including G inhibitory proteins, the Src family kinase (SFK) members src and c-fyn, and tubulin.

CD90 has been found to play a role in numerous cellular activities, such as cell adhesion, apoptosis, metastasis, inflammation, and fibrosis. In mouse strains expressing CD90.1, it is expressed on early-stage hematopoietic cells in bone marrow, thymocytes, and circulating mature T cells. The OX-7 antibody has been reported to induce leukocyte activation, glomerular nephritis, apoptosis in glomerular mesangial cells, and vascular permeability. CD90 can be used as a marker for a variety of stem cells and for the axonal processes of mature neurons. Diseases associated with CD90 dysfunction include nasopharyngeal carcinoma and thymoma.
Antigen Distribution
CD90 is present on a variety of cell types in murine and rat, including lymphatic vessels1, T cells2, neurons3 and fibroblasts4.
Function
The function of Thy1 has not been fully elucidated but is thought to play roles in regulation of cell adhesion, apoptosis, metastasis, inflammation, and fibrosis
NCBI Gene Bank ID
Research Area
Immunology

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Common In Vivo Applications of Clone OX-7 in Mice

Cellular Labeling and Lineage Tracking
Clone OX-7, targeting CD90.1 (Thy1.1), is widely used for cellular labeling and tracking in mouse strains that express this antigen, such as AKR/J, PL, and FVB/N. By binding to CD90.1 on the cell surface, it enables researchers to identify and monitor the fate of specific cell populations in vivo—particularly thymocytes, hematopoietic stem cells, T cells, and other cell types expressing CD90.1. This is valuable for stem cell research, immunology, and developmental biology studies.

Induction of Glomerulonephritis Models
A prominent application is the induction of experimental glomerulonephritis in rats as a model for human kidney diseases. Although this is most established in rats, CD90.1-expressing mice could, in theory, be used in similar models. Intravenous administration of OX-7 leads to complement-dependent cytotoxicity and subsequent glomerular injury, mimicking human nephritis. While this model is mainly rat-based, it highlights the potential for OX-7 in disease modeling where appropriate mouse backgrounds are used.

Functional Modulation of CD90.1-Positive Cells
OX-7 can functionally modulate cells expressing CD90.1 in vivo, due to its ability to crosslink and potentially deplete or activate these cells. This property is exploited for interrogating the roles of CD90.1-positive populations in immune responses, tissue repair, or other physiological processes.

Therapeutic and Drug Delivery Applications
There are experimental uses involving OX-7 F(ab)2 fragments as targeting moieties for drug delivery, especially in contexts where CD90.1 is highly expressed in specific tissues. Though most published work focuses on rats, the principle could apply to mice with the appropriate antigen.

Summary Table

Application AreaDescriptionSupported Mouse Strains
Cellular Labeling/TrackingVisualize and trace CD90.1+ cell populations in vivoAKR/J, PL, FVB/N, etc.
Disease ModelingExperimental induction of glomerulonephritis (mainly rat, possible in mice)AKR/J, PL, FVB/N
Functional ModulationModify or deplete CD90.1+ cells for functional studiesAKR/J, PL, FVB/N
Targeted Drug DeliveryUse as targeting moiety for drug-loaded nanoparticlesTheoretical (no explicit mouse data)

Key Considerations

  • Strain Specificity: OX-7 only works in mouse strains that express the Thy1.1 alloantigen variant (CD90.1), not those expressing Thy1.2 (e.g., C57BL/6, BALB/c).
  • Mechanism: Binding of OX-7 can lead to cell depletion via complement-mediated cytotoxicity, making it useful for both labeling and functional studies.
  • Limitations: Most robust in vivo applications are established in rats; mouse applications are possible but may require careful validation for each model and background.

In summary, the primary in vivo applications of clone OX-7 in mice are cellular labeling, lineage tracking, and functional modulation of CD90.1-positive cells, with potential for disease modeling and targeted therapy in strains that express the appropriate antigen.

Based on the search results, OX-7 (anti-CD90/Thy1.1 antibody) is commonly used in research alongside several other antibodies and proteins, depending on the experimental context:

Structural Reference Proteins

Beta tubulin serves as a classic companion for OX-7 in immunocytochemistry (ICC) experiments, where it functions as a structural reference marker and provides normalization for imaging studies.

Secondary Detection Antibodies

Anti-mouse IgG secondary antibodies are routinely employed with OX-7, since OX-7 is a mouse monoclonal antibody of the IgG1 isotype. These secondary antibodies enable indirect detection and visualization of OX-7 binding in various immunological assays.

Cell Marking and Visualization

In studies examining neuronal cells, OX-7 has been used in conjunction with peripherin staining to visualize sympathetic rat neurons through fluorescence microscopy. This combination allows researchers to assess neurite outgrowth, demonstrating OX-7's ability to promote neuronal development when combined with peripherin as a neuronal marker.

Complement Components

In models studying antibody-mediated cytotoxicity, OX-7 is examined alongside C3 complement protein to investigate complement-dependent cytotoxicity mechanisms. Research has utilized this combination to examine tissues including the kidney, adrenal gland, and thymus in rat anti-Thy-1 models.

The specific antibodies and proteins used with OX-7 ultimately depend on the experimental system, with the choice driven by whether researchers are conducting flow cytometry, microscopy, functional assays, or complement-mediated studies.

The OX-7 clone is a widely used rat monoclonal antibody targeting CD90 (Thy-1), and key findings from its citations in scientific literature emphasize its significant roles in cell biology and neuroscience.

Key findings include:

  • Cellular specificity: OX-7 specifically binds to CD90, a GPI-anchored membrane glycoprotein found on thymocytes, neuronal cells, hematopoietic stem cells, immature B lymphocytes, and connective tissue in rats, as well as certain mouse strains (notably those expressing the CD90.1/Thy-1.1 alloantigen, but not CD90.2/Thy-1.2).
  • Species cross-reactivity: OX-7 reacts strongly with rat CD90 and mouse CD90.1 (Thy-1.1)-positive strains (such as AKR and FVB), but not with Thy-1.2 strains (like BALB/c). It also reportedly cross-reacts with CD90 in other species, such as rabbit and guinea pig.
  • Functional applications: OX-7 is routinely used for cellular labeling, flow cytometry, lineage tracking, and sorting of cells expressing CD90 in immunological and stem cell research.
  • Neuroscience research: The antibody has been shown to promote neurite outgrowth in peripherin-stained sympathetic rat neurons, supporting its application in neurodevelopmental studies.
  • Studies on adhesion and signaling: CD90, as detected by OX-7, mediates adhesion of thymocytes to thymic stroma and participates in signal transduction processes relevant to immune cell function and development.
  • Disease models: OX-7 has been applied to induce glomerular nephritis in Wistar rats, demonstrating its functional relevance in in vivo disease settings.
  • Technical features: OX-7 is used as an in vivo functional-grade antibody for depletion or tracking of Thy-1.1–expressing cells in animal models.

Summary Table: Major OX-7 Findings

AreaKey Findings
Target SpecificityCD90 (Thy-1) on rats, mouse CD90.1 strains, cross-reacts in other species
ApplicationsFlow cytometry, cell sorting, lineage tracking, in vivo depletion studies
NeurosciencePromotes neurite outgrowth, supports neural development studies
ImmunologyMediates thymocyte-stroma adhesion, signal transduction
Disease ModelsInduces glomerular nephritis in rat models

These attributes have established OX-7 as a standard tool in research on stem cells, immunology, and neuroscience.

Dosing regimens of clone OX-7 vary significantly across different mouse models due to fundamental differences in CD90 (Thy-1) allelic variants expressed by different strains, as well as the specific experimental application being pursued. The variability in dosing protocols stems from the polymorphic nature of CD90 in mice and the diverse research contexts in which this antibody is employed.

Strain-Dependent Variations

The most critical factor affecting OX-7 dosing is the specific CD90 allelic variant present in the mouse strain. Clone OX-7 exhibits differential reactivity based on whether mice express Thy1.1 or Thy1.2 alleles. The antibody reacts strongly with Thy1.1-expressing strains such as AKR/J, FVB, and PL mice, but does not bind to Thy1.2-expressing strains including CBA and BALB/c. This fundamental difference means that OX-7 can only be used effectively in Thy1.1 mouse strains, inherently limiting its application across different mouse models.

The binding affinity itself varies between species and alleles, with the Fab′ fragment of OX-7 showing an affinity of 3 x 10⁸ M⁻¹ for mouse Thy1.1, which is tenfold lower than its 3 x 10⁹ M⁻¹ affinity for rat Thy1. This difference in binding strength likely necessitates adjustments in dosing when working with mouse versus rat models.

Application-Specific Dosing

The intended experimental application fundamentally shapes the dosing regimen employed. For flow cytometry applications, a standard approach uses 10 μL of the working dilution to label 1 x 10⁶ cells in 100 μL. However, this represents just one narrow application context, and dosing protocols are not standardized across different experimental purposes.

The detection method being used also influences dosing decisions. Different analytical techniques—whether flow cytometry, fluorescence microscopy, or other immunological assays—require optimization of antibody concentration to achieve optimal signal-to-noise ratios and minimize background staining.

Functional Study Variations

Beyond detection and analytical applications, functional studies using OX-7 demonstrate additional dosing complexity. The antibody has been used to promote neurite outgrowth in peripherin-stained sympathetic rat neurons, and has been reported to induce glomerular nephritis in Wistar rats. These diverse biological effects suggest that dosing must be carefully calibrated based on whether the goal is cell labeling, functional modulation, or disease induction.

The lack of standardization across protocols means that exact dosing regimens are typically determined empirically for each specific combination of mouse strain, experimental model, and research objective. Researchers must consider the interplay between strain genotype, binding affinity, desired biological effect, and detection methodology when establishing appropriate dosing protocols for clone OX-7 in their particular mouse model system.

References & Citations

1. Jurisic G, Iolyeva M, Proulx ST, et. al. Exp Cell Res. 316: 2982–2992. 2010.
2. Ledbetter JA, Rouse RV, Micklem HS, et. al. J Exp Med. 152: 280–295. 1980.
3. Schrader JW, Battye F, Scollay R. Proc Natl Acad Sci. U S A 79: 4161–4165. 1982.
4. Phipps RP, Baecher C, Frelinger JG, et. al. Eur J Immunol. 20: 1723–1727. 1990.
5. Hu P, Leyton L, Hagood JS, Barker TH. Front Cell Dev Biol. Jun 6;10:928510. 2022.
6. Crook K, Hunt SV. Dev Immunol. 4(4):235-46. 1996.
7. Zhang J, Wang JH. Methods Mol Biol. 1842:217-228. 2018
8. Hermans MH, Opstelten D. J Histochem Cytochem. Dec;39(12):1627-34. 1991
Flow Cytometry
IF
IHC

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.